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Aims: Pro-oxidant iron provides a potential measure of iron-catalysed oxidative stress in bio-
logical fluids. This study aimed, to investigate if the Bleomycin technique for measurement
of pro-oxidant iron in biological fluids could be utilised for determinations in exhaled breath
condensate (EBC). Secondly, to measure levels of pro-oxidant iron in EBC from asthmatics after
exposure to polluting city environments.
Methods: Retrospective analysis of samples of EBC and bronchoalveolar lavage fluid (BALF).
Pro-oxidant iron levels were determined by the Bleomycin method. Transferrin levels were
determined by radial diffusion immunoassay and lactoferrin by ELISA.
Subjects: : Patients undergoing surgery necessitating cardiopulmonary bypass, normal healthy
controls, "healthy" smokers, and asthmatics (mild and moderate).
Results: Pro-oxidant iron was significantly decreased (p< 0.05) post cardiac surgery in both
EBC and BALF. In smokers levels of pro-oxidant iron in EBC were significantly (p < 0.05)
increased verses healthy controls. In asthmatics with more severe disease, there were signif-
icant increases in EBC pro-oxidant iron content post exposure to city environments (p< 0.001),
with levels most elevated after exposure to the most polluted setting.
Conclusion: Similar patterns in the levels of pro-oxidant iron detectable in EBC and paired
BALF from patients undergoing cardiopulmonary bypass (pre and post surgery) suggest a poten-
tial for EBC determinations. Significantly elevated levels in EBC from smokers relative to
control subjects provide further support for this technique. In asthma disease severity and
environmental exposure influenced levels of pro-oxidant iron measured in EBC indicating
a potential for enhanced iron-catalysed oxidative stress.
ª 2011 Elsevier Ltd. All rights reserved.207 351 8218; fax: þ44 0 207 351 8524.
l.ac.uk (S. Mumby).
1 Elsevier Ltd. All rights reserved.
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MethodsIron catalysed electron transfer reactions activate oxygen by
forming reactive oxygen species (ROS) so enabling metabolic
utilisation. Under such circumstances iron is located within
active sites or prosthetic groups of bio-molecules (chiefly
proteins); all such purposeful responses involving iron and
ROS are therefore strictly controlled by the local environ-
ment. However, once free of such constraints, iron is capable
of catalysing the uncontrolled formation of an array of ROS,
many of which are aggressive species that can cause direct
oxidative damage and dysfunction to bio-molecules. Iron
transporting proteins such as transferrin and lactoferrin, and
iron storage proteins such as ferritin, sequester iron in forms
that minimise the transfer of electrons from iron to molec-
ular oxygen. However the storage capacity for iron can be
exhausted leading to the presence of free pro-oxidant iron in
biological samples which can stimulate iron-driven oxidative
reactions contributing to damage and dysfunction. The
Bleomycin assay1 was developed to measure this pool of free
pro-oxidant iron, and has subsequently been utilised exten-
sively to determine pro-oxidant iron content in a range of
biological fluids in both health and disease.2 In essence the
assay utilises bleomycin (a drug which is derived from
a bacterial siderophore) to chelate iron whilst binding to the
target molecule DNA. Redox cycling of iron by molecular
oxygen releases malondialdehyde from the deoxyribose
sugar of DNA, which can then bemeasured and related to the
amount of free iron present.
Emerging evidence indicates that exposure to and
handling of iron within the lungs may have consequences
relating to the pathology of an array of respiratory diseases
including chronic lung disease in preterm infants,3 cystic
fibrosis,4 oxidative damage related to asbestos exposure,5
ozone mediated lung injury,6 respiratory impairment
related to chronic exposure to iron ore,7 asthma,8 and
COPD.9 Moreover, a study undertaken utilising the bleo-
mycin assay, described the presence of pro-oxidant iron in
bronchoalveolar lavage fluid obtained from patients with
acute lung injury together with elevated levels of total non-
haem iron.10 Lung specific and systemic oxidative stress is
associated with the onset and progression of this disease
process as is abnormal iron-handling reviewed in.11
However interestingly, a small pool of pro-oxidant iron
was detectable in samples obtained from normal healthy
controls.10 This finding was somewhat unexpected given
that in all other biological fluids examined from normal
healthy individuals no such pro-oxidant iron has been found
apart from in the trunk fluid sweat of athletes.12 It there-
fore appears that the lungs are uniquely exposed to pro-
oxidant iron on an ongoing basis, most likely as a conse-
quence of atmospheric exposure.13 Therefore in the
current study, we assessed whether exhaled breath
condensate (EBC) sampling could be utilised to assess levels
of and catalytic potential of this extracellular pro-oxidant
iron pool in the lung, by comparing the results in EBC
with those measured in BAL fluids. We also used this tech-
nique to assess whether environmental oxidative stress
represented by chronic cigarette smoking or by exposure to
environmental pollution could modify the levels of pro-
oxidant iron measured in this way.The study had Ethical approval from the Royal Brompton and
Harefield NHS Trust. All patients gave informed consent.
Patients
Patients undergoing coronary artery bypass graft
Twenty-six patients (21 males; median age 64 (range
56e72) years) undergoing coronary artery bypass graft
(CABG) surgery participated in the study. EBC and BALF
were collected prior to surgery following anaesthesia and
30 min after termination of surgery. These samples were
originally obtained for another study which is published and
includes the patient demographics.14
Non-smokers and smokers
EBC was collected from 21 healthy non-smokers (14 male,
median age 30.2 years (range 22e49) and 7 “healthy”
smokers (5 male, median age 32.6 years (range 25e42).
Both healthy non-smokers and “healthy” smokers had
normal FEV1/FEC> 70% and FEV1 >80% predicted.
“healthy” smokers were all current smokers with a pack
year history of 20  15 pack years.
Asthmatic population
EBC was collected and examined from 54 asthmatic
patients who took part in a study that examined the effects
of atmospheric pollution of Oxford Street and Hyde Park in
London UK on respiratory impairment,15 the patient
demographics are included in this study. 30 patients had
mild asthma (16 male, median age 26.5 (range 19e48)
years) and 24 patients had moderate asthma (13 male,
median age 29.5 (range 19e55 years). EBC was collected
pre-exposure, and at 1 and 4 h post exposure, with each
individual being exposed to each environment (Oxford
Street or Hyde Park) on different days.
Severity of asthma (mild and moderate) were defined as
described previously15 utilising the Global Initiative for
Asthma (GINA) home page, (Accessed November 9, 2007 at
www.ginaasthma.com/Guidelineitem.asp).
Patients were in the main atopic as defined by positive
skin prick tests to at least one of more common aero-
allergins; 89% of mild and 78% of moderate asthmatic
patients were atopic.
Collection of EBC and BAL fluid
EBC from surgical patients
EBC was collected from intubated patients undergoing
cardiopulmonary bypass surgery before and 30 min after
surgery. The fraction of inspired oxygen was 0.4e0.5 and the
tidal volume was standardized at 10 ml/kg during EBC
collection.Humidification, in the formof aheat andmoisture
exchanger (Hydro-Therm HME; Intersurgical Ltd., Berkshire,
UK) was disconnected from the ventilator tubing a minute
before EBC collection was started. Exhaled breath flowed
through a one-way valve into a polypropylene collection tube
which was cooled by a surrounding aluminium sleeve at
20 C. (Rtube; Respiratory Research Inc., Charlottesville,
VA.). Collection was carried out for 15 mins.
Figure 1 A. Levels of pro-oxidant iron in exhaled breath
condensate (EBC) obtained from patients undergoing cardio-
pulmonary bypass surgery (n Z 26) are shown. )indicates
p < 0.05 compared to pre-operative levels. B. Levels of pro-
oxidant iron in bronchoalveolar lavage fluid (BALF) from
patients undergoing cardiopulmonary bypass (n Z 26) are
shown. )indicates p < 0.05. For both Fig. 1A and B Pre-op
indicates pre-operative samples and Post-op post-operative
samples.
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EBC was collected using a specially designed condensing
chamber (Ecoscreen; Jaeger, Hoechberg, Germany).
Exhaled air entered and left the chamber through one-way
valves at the inlet and outlet, thus keeping the chamber
closed. Subjects breathed tidally through a mouthpiece
connected to the condenser for 15 min while wearing nose
clips. A 20 C temperature inside the condensing chamber
throughout the collection time produced immediate sample
freezing. Approximately 2.5 ml of breath condensate was
collected.
BAL fluid from surgical patients
Bronchoalveolar lavage was performed after EBC collec-
tion, using buffered normal saline (3 aliquots of 60 ml), in
different segments of the right middle lobe of the lung
before and after cardiac surgery. The fluid was centrifuged
and stored at 80 C. Total protein in BALF was measured
using a kit from Sigma (Poole, Dorset, UK) based on the
Lowry method.
Pro-oxidant iron measurement
Pro-oxidant iron in EBC and BALF was measured using the
Bleomycin assay.16 Briefly, the reaction mixture contained
DNA, Bleomycin and the sample buffered to pH 7.4 with
a Tris buffer. In the presence of added ascorbate, iron that
is able to be chelated from the sample by bleomycin can
degrade DNA in vitro with the release of malondialdehyde
from its deoxyribose moiety. The released malondialdehyde
can be measured spectrophotometrically (A532nm) by reac-
tion with 2-thiobarbituric acid. Adventitious iron in
reagents was removed as previously described.17 The pro-
oxidant iron was quantitated with reference to pure iron
standards. The between batch percentage coefficient of
variation of this assay was 4.3%.
Transferrin and lactoferrin levels in BAL
Transferrin in BALF was determined by radial immunodif-
fusion using a polyclonal antibody to pure standards of
human apotransferrin (Dade Behring).
The level of Lactoferrin in BALF was assayed using an
ELISA kit (Merck Bioscience, UK).
Data analysis
All data were analysed using Prism 4 (Graphpad) software.
A T-test was used for statistical analysis of data from two
groups. Analysis of data from asthmatic patients was ana-
lysed using repeated measures ANOVA. p < 0.05 was
considered significant.
Results
To investigate the potential for pro-oxidant iron measure-
ment in EBC, and to evaluate the technique as a non-
invasive alternative to BALF sampling and measurement,
we compared EBC with paired BALF measurementsobtained pre and post-operatively from patients undergoing
surgery necessitating cardiopulmonary bypass (CPB)
n Z 26. Post-operative EBC pro-oxidant iron levels were
significantly (p Z 0.014) decreased compared to pre-
operative levels (136.7  29.73 v 86.69  13.13 nM; see
Fig. 1A). Importantly, a similar set of significant (pZ 0.037)
results were obtained from determinations of pro-oxidant
iron in bronchoalveolar lavage fluid (BALF) (2.308  0.464
pre-operatively compared to 1.446  0.201 nM/mg protein
post op; see Fig. 1B); there was no correlation between
these variables.
In order to assess the utility of this technique as a means
of determining the influence of the exposure to iron on the
respiratory system, an allied study of EBC pro-oxidant iron
content was undertaken in samples obtained from normal
healthy controls (n Z 21), and “healthy” smokers (n Z 7).
Pro-oxidant iron levels were significantly (p < 0.01)
elevated in EBC from “healthy” smokers (205.9  29.47 nM)
compared to non-smokers (62.95  23.76 nM) (Fig. 2).
To examine the effects of environmental exposure on
EBC pro-oxidant iron content in patients with asthma,
samples obtained from a previous environmental exposure
study were utilised.15 Data were categorised based on
severity of disease, time of sample collection and location
Figure 3 A. Levels of pro-oxidant iron in exhaled breath
condensate obtained from mild asthmatics (nZ 30) are shown.
Open bars represent exposure to the Hyde Park environment
and solid bars Oxford Street. B. Levels of pro-oxidant iron in
exhaled breath condensate obtained from moderate asth-
matics (n Z 24) are shown. Open bars represent exposure to
the Hyde Park environment and solid bars Oxford Street.
p < 0.001 by ANOVA for both Hyde Park and Oxford Street
exposure.
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In patients with asthma (n Z 54), pre-exposure mean
EBC pro-oxidant iron levels were not significantly different
from those seen in normal healthy controls subjects
(n Z 21) (87.18  8.48 nM compared to 62.95  23.76 nM
respectively, p > 0.05) indicating firstly that this form of
pro-oxidant iron is detectable in EBC and secondly that the
levels of pro-oxidant stress is similar in both populations.
In mild asthmatics, after exposure to either Oxford Street
or to Hyde Park air, there were no significant changes in EBC
pro-oxidant iron content over time (1 and 4 h post exposure)
(Fig. 3A). However, in patients with (more severe) moderate
asthma, there were significant increases in EBC pro-oxidant
iron content on exposure to both Oxford Street and Hyde
Park (p < 0.001 ANOVA in both cases; Fig. 3B).
Discussion
Studies to determine pro-oxidant iron content in both EBC
and BALF of patients undergoing cardiopulmonary bypass
surgery revealed similar trends pre to post surgery, with
levels showing significant decreases in both cases (Fig. 1A
and B). However, no absolute correlation between these
variables was apparent (data not shown). Although both
techniques show similar changes in pro-oxidant iron, lack of
correlation limits interpretation of any potential relation-
ship between these sampling techniques. One possible
explanation for this discrepancy may relate to the areas of
the respiratory system sampled; the BAL technique being
limited to specific areas of the lower lung, whereas EBC
samples both lung and airways.
As for possible explanations for the overall results
obtained, the diminished pro-oxidant iron content of both
lung and breath post-operatively may reflect the up-
regulation of protective stratagems designed to limit
extracellular iron availability. Indeed the iron-binding
proteins transferrin and lactoferrin are both present preFigure 2 Levels of pro-oxidant iron in exhaled breath
condensates obtained from normal healthy non-smokers
(nZ 21).and smokers (nZ 7) are shown. )) indicates p < 0.01.(0.50  0.057 mg/mg protein, 1.25  0.34 ng/mg protein
respectively) and in post-operative BALF (0.45  0.033 mg/
mg protein, 3.32  0.95 ng/mg protein respectively) with
lactoferrin being significantly (p < 0.05) elevated. Both
proteins will have a variable reserve of iron already bound
which will ultimately determine spare capacity for iron-
binding in the lung during CPB. Thus although changes in
lactoferrin content may offer an explanation for the
decrease in pro-oxidant iron levels seen post-operatively
this cannot be concluded here. Physiological changes such
as altered pH also influence iron-binding potential of these
proteins. Consideration should also be given to influences
related to the use of inhaled gases which may influence EBC
measurements in this particular patient group thus the use
of an additional time point for EBC collection may well
provide information on pro-oxidant iron levels in this
patient population. Indeed measuring indices in EBC over
differing time frames does influence results in respiratory
diseases.18 Alternatively, the presence of pro-oxidant iron
in EBC may represent a manifestation of a protective
excretory stratagem, in which case the decreases seen here
(post-operatively) may equate to some form of dysfunction
or vulnerability. Interestingly, a degree of lung injury is
a recognised complication of this type of surgery.19
Furthermore, changes in lung specific and systemic iron
chemistry are also associated with cardiopulmonary bypass
procedures, reviewed in.20
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normal healthy controls and “healthy” smokers revealed
significantly elevated levels of pro-oxidant iron in the
smoking population. This result is not unexpected as iron is
one of a range of metal components found in cigarette
smoke,21 and additionally particulate matter within smoke
alters lung and systemic iron homeostasis.22 The results
presented here therefore demonstrate the considerable
iron-catalysed oxidant burden imposed on the lung by an
active smoking habit, but also potentially a functioning
excretory mechanism. The overlap in levels of some deter-
minations between groups may indicate some intra-
individual variability and also potential influences of
differing previous environmental exposure. Comparisons of
EBC pro-oxidant iron levels in “healthy” smokers and those
with COPD both active and former smokers may provide
further understanding of this potential excretory stratagem.
Studies to investigate the influence of exposure to
polluting environments on pro-oxidant iron levels in EBC
from patients with asthma, were undertaken utilising
appropriately stored samples collected for a previous study
(see results). Iron is a known component of automobile
exhaust emissions23 and in the redox active form is an avid
catalyst for the formation of damaging reactive oxygen
species. Iron therefore has potential implications related to
exhaust emission associated respiratory disease/impair-
ment as mediated by oxidative stress. In the previous
environmental exposure study, the composition of the
pollutants to which asthma patients were exposed to has
been reported,15 with Oxford Street being the more
polluted environment. Indeed this study showed that
walking for 2 h on Oxford Street induced asymptomatic but
consistent reductions in the forced expiratory volume in 1 s
(FEV1) (up to 6.1%) that were significantly larger than the
reductions in FEV1 after exposure in Hyde Park. The effects
were also greater in subjects with moderate asthma rather
than those with mild asthma.
We therefore utilised EBC samples obtained from
a cohort of these patients to examine the influence of
differing environments on levels of pro-oxidant iron.
Patients when grouped based on severity of asthma and
also environmental exposure showed no significant differ-
ences in EBC pro-oxidant iron levels for mild asthmatics pre
to post (1 and 4 h) exposure for either environment (Fig. 3A)
which may indicate that this patient cohort is better pro-
tected against iron-catalysed oxidative stress in the lung.
However, significant increases were seen in moderate
asthmatics post exposure for both environments (Fig. 3B).
The greatest increase was observed at 4 h after exposure to
the more polluted environment of Oxford Street with levels
well in excess of those detected on any occasion previously
in these asthmatic patients. As pro-oxidant iron is a good
indicator of damaging oxidative stress, these results
suggest an increased oxidant burden from environmental
exposure in the lungs of patients with more severe asthma.
Moreover the delay in response time for increased EBC pro-
oxidant iron excretion may suggest heightened vulnera-
bility in this patient group.
In this regard recent studies utilising exhaled breath
condensate (EBC) sampling and atomic absorption spectro-
photometry (AAS) detection have demonstrated elemental
iron and other metals in asymptomatic smokers, andpatients with asthma or COPD.24 Interestingly, levels of iron
were significantly decreased in smokers and asthmatics,
compared to normal healthy controls.24 At first glance these
results seem at variance with those presented here.
However, the techniques utilised to measure metals in EBC
were largely undertaken by atomic absorption spectropho-
tometry (AAS); as the authors acknowledge such methods
give accurate values of total metal content, but do not give
information about physical states; such as the nature of
metal containing complexes or the ionic state of variable
valence metals. Such considerations are paramount in
assessing the role of these agents in health and disease.
The pro-oxidant iron technique adopted by us seeks to
address some of these issues by measuring the catalytic
activity of a specific iron pool rather than providing a total
elemental measurement. Thus, although total iron levels
may be decreased in EBC in asthmatics and smokers24 an
increased iron-driven pro-oxidant potential is apparent in
these groups which has implications for enhanced levels of
extracellular oxidative stress in the respiratory systems of
these individuals and also excretory function.
Differences in responses between patients at risk of acute
lung injury (cardiopulmonary bypass) in which EBC pro-
oxidant iron decreased post-operatively and moderate
asthmatics which exhibit delayed but ultimately increased
levels of pro-oxidant iron after exposure to atmospheric
pollution may ultimately be a reflection of the disease
processes involved; acute lung injury being primarily a lung
parenchymal injury whilst asthma is a disease of the airways.
In this regard it is noteworthy that the cellular expression of
the iron excretion protein ferroportin is confined to the
apical surface of broncho-epithelial cells alone and is not
expressed by alveolar epithelial cells.25 The lack of an
identifiable cellular iron excretion protein in the alveolar
epithelium may help explain vulnerability of the alveoli to
oxidative stress in disease processes such as ARDS.
The nature and extent of these observational studies
does not allow for investigation of a potential biological
mechanism(s) that may influence the excretion of pro-
oxidant iron in EBC. However, it is well established that an
array of particulates including components of cigarette
smoke and atmospheric pollution contain high iron
concentrations. Uptake of these particles by the respiratory
epithelium and resident inflammatory cells is an estab-
lished process and has been linked to the pathogenesis of
both asthma and COPD. Importantly, ferroportin, a cellular
iron export protein has been identified on alveolar macro-
phages and on the apical surface of bronchial epithelial
cells.25 The presence of this export protein suggests
a potential route for pro-oxidant iron excretion into the
airspace after cellular processing of iron containing parti-
cles. Such processes are likely to be important for several
reasons: Firstly, the presence of excess cellular iron accu-
mulation may contribute to the deleterious pro-oxidant,
pro-inflammatory and proliferative responses13,20 and
secondly release of iron in this free ionic form aids solu-
bility and most probably ease of excretion in breath. An
investigation into the expression and activity of ferroportin
would therefore seem to be an appropriate means of
extending these intriguing observations and may contribute
to a better understanding of key aspects of the pathogen-
esis of respiratory diseases including asthma and COPD.
Pro-oxidant iron in exhaled breath condensate 1295Conclusions
In summary, these studies demonstrate for the first time
that the Bleomycin method for pro-oxidant iron measure-
ment in biological fluids can be applied for the same
determinations in EBC. Therefore this technique may
provide a non-invasive means of assessing pro-oxidant iron
status within the airways and lungs.
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